Pharmaceutical Venture Capital Conference: The next five years will be a key opportunity period for the transformation and upgrading of China's biomedicine
- Categories:Industry News
- Author:
- Origin:
- Time of issue:2020-10-15
- Views:0
(Summary description)In-depth focus on industrial policies, global pharmaceutical R&D trends, and investment and financing trends, comprehensively discuss global pharmaceutical innovation development trends, and discuss new developments in biomedical investment cooperation. On September 27, 2020, the Fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Investment Conference") kicked off in Suzhou Industrial Park.
Pharmaceutical Venture Capital Conference: The next five years will be a key opportunity period for the transformation and upgrading of China's biomedicine
(Summary description)In-depth focus on industrial policies, global pharmaceutical R&D trends, and investment and financing trends, comprehensively discuss global pharmaceutical innovation development trends, and discuss new developments in biomedical investment cooperation. On September 27, 2020, the Fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Investment Conference") kicked off in Suzhou Industrial Park.
- Categories:Industry News
- Author:
- Origin:
- Time of issue:2020-10-15
- Views:0
Information
In-depth focus on industrial policies, global pharmaceutical R&D trends, and investment and financing trends, comprehensively discuss global pharmaceutical innovation development trends, and discuss new developments in biomedical investment cooperation. On September 27, 2020, the Fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Investment Conference") kicked off in Suzhou Industrial Park. Simcere Pharmaceuticals and other well-known pharmaceutical companies, experts in the pharmaceutical industry, and investment circles attended the conference.
At the meeting, Ren Jinsheng, the annual president of China Pharmaceutical Innovation Promotion Association and chairman and CEO of Simcere Pharmaceuticals, delivered a speech on behalf of the organizer: "Currently, China's biomedical industry is facing many uncertainties and unprecedented challenges. The next five years will be China A key opportunity period for the transformation and upgrading of biomedicine.
Patients regardless of race or national borders. China's pharmaceutical innovation and investment should not only pay attention to the internal circulation of market and resource elements, but also make good use of Chinese elements and Chinese advantages, be aggressive, bold and promising, and make greater efforts to promote foreign exchanges and cooperation. Use openness and cooperation to promote higher-level innovation and investment. Let us keep in mind the noble mission of helping patients, adhere to open innovation, and contribute China's strength to innovation and investment in the global life sciences field. "
Song Ruilin, Executive Chairman of China Pharmaceutical Innovation Promotion Association, presided over the opening speech of the conference. Ren Jinsheng, Annual Chairman of China Pharmaceutical Innovation Promotion Association, Chairman and CEO of Simcere Pharmaceuticals, Li Xiaojia, Chief Executive Officer of Hong Kong Stock Exchange Group, and Deputy Secretary of Suzhou Municipal Committee , Suzhou Mayor Li Yaping delivered a speech on behalf of the organizer, warmly welcome all leaders, experts and colleagues in the investment and medical circles, and wish the conference a complete success. Chen Deming, former minister of the Ministry of Commerce and chairman of the China Association of Enterprises with Foreign Investment, and Shang Fulin, director of the Economic Committee of the CPPCC National Committee and former chairman of the China Banking Regulatory Commission, delivered speeches at the opening ceremony.
Big data and omics-driven medicine bring new challenges
Professor Wang Yongjun, Dean of Beijing Tiantan Hospital Affiliated to Capital Medical University, delivered a speech entitled "Innovative Drug Development from the Perspective of Clinical Research", describing the health industry driven by big data and omics. Professor Wang Yongjun said that after the arrival of high-definition medicine, big data and omics-driven medicine have brought new challenges to new drug development and clinical medicine. From the perspective of industrial structure, the industrial structure promoted by omics and clinical big data can be roughly divided into five categories, including health big data, medical blockchain, medical artificial intelligence companies, reverse drug development, etc., which are all driven by big data. Come.
He also mentioned: "On July 30 this year, we promoted the launch of Simcere's innovative neuroprotective drug edaravone and dexcamphanol injection concentrated solution (trade name: Xianbixin®). The result of ten years of working together. This is the use of the powerful clinical evaluation function of the National Center ARO."
Talk about the global pharmaceutical innovation development trend
In the discussion session of "Global Pharmaceutical Innovation Development Trends", He Ruyi, the former chief scientist of the CFDA Drug Evaluation Center, said: "Although China has developed very well in innovative drugs in recent years, it is necessary to recognize the gap with the international advanced level. I personally feel that Easy to achieve breakthroughs One of the key points of new drug research and development is biological drugs, and the second is improved new drugs. This is our strength. In addition, some new technologies such as gene therapy will also have breakthroughs in the next few years and will catch up with the world's advanced Level."
How to pay for valuable innovations is the focus of RDPAC CEO Conway’s focus. “In terms of national medical insurance fund expenditures, compared with other advanced countries, the structure of innovative drugs still accounts for a small proportion, probably in innovative drugs. Such truly patentable products may be less than 10%, and developed countries are at least 50% to 60%. We can also see that the country is also undergoing industrial adjustments and policy guidance to increase valuable innovation input. Medical insurance funds are limited. How to explore diversified payment and commercial insurance in the future requires the joint efforts of the industry."
Jiang Jiandong, the 2017-2018 President of the China Association for the Promotion of Medicines and Director of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, said: ``The new crown epidemic has changed many previous views of the industry. For example, in the past, it was believed that infectious diseases such as tuberculosis, polio, AIDS, and hepatitis B were basically All are well controlled, but the sudden new crown epidemic has caused a great impact on the world. Related vaccine research and drug research have become the focus, which suggests that we actually have many unknown infectious diseases that need to be better Take control."
Li Ning, CEO of Junshi Bio, believes that the future of innovative drug companies is bright, and the road is tortuous. How can this road be unified and coordinated in government policies and talent training? This is the survival of innovative drug companies. The fundamental element is also a question that must be considered in China's pharmaceutical innovation.
Chairman Song Ruilin recognized their views and concluded: "Research on global pharmaceutical innovation trends should have its own characteristics, which are in line with China's national conditions but at the same time cannot lag behind the development of the whole world. How can innovative companies be based in China and look at the world? We must not only pay attention to current clinical needs and world needs, but also look to global development."
In addition, Ren Jinsheng, Chairman and CEO of Simcere Pharmaceuticals mentioned at the conference, let us keep in mind the noble mission of helping patients, adhere to open innovation, and contribute China's power to innovation and investment in the global life sciences field. In this regard, Simcere will use practical actions to fulfill its mission.
Scan the QR code to read on your phone
13648401148
SERVICE 
Tel：+86 23 67231349 M：+86 13648401148
Email：wuhy@asincanbio.com; sales@asincanbio.com; wuhy51@hotmail.com
QQ：2665283306
Wechat：+86 13648401148
Skype：wuhy51
Chongqing Asincan Biotech Co.,Ltd.
Copyright © 2020 Chongqing Asincan Biotech Co.,Ltd.